14 min. read
10.02.20

Five investors talk digital therapeutics: Red flags, starting up, and COVID–19

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

At the virtual DTx East conference in September, five active investors with a focus on digital therapeutics discussed the market. Here are four of the topics they dug into:

  • What they look for in potential investment targets
  • Red flags when evaluating a digital therapeutic startup
  • What startups should look for in investors
  • How COVID--19 has just been a speedbump for some and created tailwinds for others
  • And more...

Here are the panelists and notes from their self-introductions:

Caleb Winder, Managing Director, MemorialCare Innovation Fund

We are focused on investing in healthcare companies across the US in early Series B or later.

Chihiro Hosoya Head of Venture Management & Business Development, Rx+ Business Accelerator Astellas Pharma

Astellas is a pharmaceutical company based in Japan but we operate globally. My scope includes both digital and devices, so we are super interested in

×

Recent Articles